 At SRI, and in collaboration with the SRI wholly owned for profit subsidiary, Sarnoff Corporation, Zarling helped organize, secure funding for and co-led a biotechnology platform based product development group.This group was responsible for significant new business and product development, including IP and product candidates, which were successfully out-licensed.Zarling was also an Associate Adjunct Professor at the University of California San Francisco and has had several successful collaborations with clinical and pre-clinical investigators at major cancer and other research centers.